💊 Pfizer India Ltd – The OG MNC Pharma Stock With a Boring but Rich Personality
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
🧠 At a Glance
Pfizer India is the desi arm of Pfizer Inc., one of the world’s biggest drug giants. Despite holding blockbuster molecules, the India unit is a low-growth, high-profit machine that moves like your neighbourhood pension uncle – slow, steady, and always giving dividends.
1. 🧬 WTF Do They Even Do?
Engaged in manufacturing, marketing, and trading of pharma products
Uses both own facilities and contract manufacturing partners
Entirely India-focused, no exports of significance
Major brands include Shelcal (calcium), Becosules (multivitamins), Corex, and Prevenar 13 (vaccine)
2. 💰 Financials Snapshot (FY25)
Metric
Value
Revenue
₹2,281 Cr
Net Profit
₹768 Cr
OPM
33%
EPS
₹167.79
ROCE / ROE
22% / 16%
Dividend Declared
₹165/share
Payout Ratio
119% 😳
3. 🧾 Valuation – Is It Cheap or Just Elite Tax Saving?
P/E Ratio: ~41x
Dividend Yield: 0.61%
CMP/BV: 6.2x
Comparables like Sun Pharma, Cipla trade at ~20–35x
💭 Verdict: Not cheap. Priced like it’s made of monoclonal antibodies. But elite investors hold it more for
